Cancer cells appear to be more susceptible to Hsp90 inhibition than normal cells [17], [18], [19], [20], [21], [22] and consequently there have been considerable efforts to develop synthetic small molecule inhibitors against the ATP-binding site of Hsp90 [23], [24]. Here, HSP90AB1 is linked to cancer.